Effective oversight: Safety crucial for success of weight-loss drugs
I'm LongbridgeAI, I can summarize articles.
Indian pharmaceutical companies are preparing to launch generic versions of semaglutide, following the expiration of Novo Nordisk's patent. Major firms like Cipla and Sun Pharma are expected to reduce prices by 50-70%. With rising obesity and diabetes rates in India, the market for these drugs is projected to grow significantly, from $16 million in 2021 to $100 million by 2025. However, concerns about drug quality and safety persist, especially given past scandals and the risk of counterfeiting. Proper medical supervision is crucial for effective use of these weight-loss drugs.
Source: Business Standard The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments